Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gentian Diagnostics ASOSL:GENT +3.19%72 3-1 Month Momentum % is 2.20% as of Aug. 24, 2026. GuruFocus rates OSL:GENT with a GF Score™ of 72/100 and a GF Value™ of kr59.79 (Significantly Undervalued). Among 849 Medical Devices & Instruments companies, Gentian Diagnostics AS ranks better than 72.67% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-24), Gentian Diagnostics AS's 3-1 Month Momentum % is 2.20%.
The industry rank for Gentian Diagnostics AS's 3-1 Month Momentum % or its related term are showing as below:
OSL:GENT's 3-1 Month Momentum % is ranked better than 72.67% of 849
companies
in the Medical Devices & Instruments industry
Industry Median: -6.25
vs OSL:GENT: 2.20
Gentian Diagnostics AS (OSL:GENT) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Gentian Diagnostics AS 3-1 Month Momentum % Related Terms
OSL:GENT vs ABT, SYK, MDT: 3-1 Month Momentum % Comparison
For the Medical Devices subindustry, Gentian Diagnostics AS's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gentian Diagnostics AS 3-1 Month Momentum % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Gentian Diagnostics AS's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Gentian Diagnostics AS's 3-1 Month Momentum % falls into.
Gentian Diagnostics AS (OSL:GENT) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gentian Diagnostics AS (OSL:GENT) has a 3-1 Month Momentum % of 2.20% as of Aug. 24, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Gentian Diagnostics AS and its competitors. According to the industry distribution chart, Gentian Diagnostics AS ranks #232 out of 849 companies in the Medical Devices & Instruments industry, placing it in the top 27.3%.
Is Gentian Diagnostics AS's 3-1 Month Momentum % too high?
Gentian Diagnostics AS's current 3-1 Month Momentum % is 2.20%. Based on the distribution chart, Gentian Diagnostics AS ranks #232 out of 849 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Gentian Diagnostics AS has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gentian Diagnostics AS's 3-1 Month Momentum % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Gentian Diagnostics AS ranks #232 out of 849 companies for 3-1 Month Momentum %. This puts Gentian Diagnostics AS in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Devices & Instruments company?
A good 3-1 Month Momentum % depends on the Medical Devices & Instruments industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Gentian Diagnostics AS and its competitors. Gentian Diagnostics AS's current 3-1 Month Momentum % is 2.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gentian Diagnostics AS stock overvalued right now?
Based on GuruFocus' analysis, Gentian Diagnostics AS (OSL:GENT) is currently considered Significantly Undervalued. The stock's GF Value™ is kr59.79, compared to a current price of kr38.80 — trading 35.1% below its estimated fair value. The current 3-1 Month Momentum % is 2.20%. Gentian Diagnostics AS's overall GF Score™ is 72/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Gentian Diagnostics AS (OSL:GENT), the current 3-1 Month Momentum % is 2.20% as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gentian Diagnostics AS (OSL:GENT) Overvalued in 2026?
Based on GuruFocus' analysis, Gentian Diagnostics AS stock appears to be undervalued.
The current stock price of kr38.80 is trading 35.1% below its estimated GF Value™ of kr59.79.
GuruFocus considers Gentian Diagnostics AS to be Significantly Undervalued.
Key valuation signals for OSL:GENT:
3-1 Month Momentum %: 2.20%
GF Value™: kr59.79 vs. price of kr38.80 (35.1% below fair value)
No single metric tells the full story. See the OSL:GENT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in vitro diagnostic reagents (IVD) for medical diagnostics and research. Its portfolio and pipeline of reagents span areas such as inflammation, severe infections, kidney diseases, heart failure, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP, among others. Geographically, it generates a majority of its revenue from Europe, followed by Asia and the United States of America.
72GF Score
Get the complete analysis for OSL:GENT
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:GENT has been successfully added to your 
